SQZ Biotechnologies Announces Integrated Point-of-Care Cell Therapy Manufacturing System Demonstrated Comparable or Better Performance Than a More Conventional Clean Room-Based Process
SQZ Biotechnologies (NYSE: SQZ) announced today that the companys first generation, integrated point-of-care (POC) cell therapy manufacturing system demonstrated superior process performance and comparable or improved product specifications relative to current clean room-based processes used in clinical development.
- SQZ Biotechnologies (NYSE: SQZ) announced today that the companys first generation, integrated point-of-care (POC) cell therapy manufacturing system demonstrated superior process performance and comparable or improved product specifications relative to current clean room-based processes used in clinical development.
- Our current clinical manufacturing process is under 24 hours - comparatively faster than other cell therapy manufacturing approaches.
- We look forward to its planned first clinical use in our red blood cell derived SQZ TAC program for celiac disease.
- The SQZ POC manufacturing system integrates and automates, among other things, cell isolation, cell washing, Cell Squeeze intracellular delivery technology, and product filling.